Node-RADS与ESGAR标准在直肠癌MRI淋巴结评估中的比较
本研究回顾性纳入780例直肠癌患者,比较Node-RADS与ESGAR标准在MRI淋巴结评估中的诊断效能。Node-RADS在淋巴结水平和患者水平均优于ESGAR标准,且简化版recSNAP具有相似的诊断性能。观察者间一致性为实质性。
要点
- Node-RADS在淋巴结和患者水平均优于ESGAR标准,可优先用于直肠癌MRI淋巴结评估。
- 直接手术患者Node-RADS阈值≥3,新辅助放化疗后阈值≥4时诊断效能最佳。
- 简化版recSNAP模型可简化评估流程,且诊断性能与原版Node-RADS相当。
核心结论
- Node-RADS在直肠腺癌MRI淋巴结评估中,无论淋巴结水平还是患者水平,均优于ESGAR标准,且在外部队列中得到验证。
- 简化版Node-RADS(recSNAP)展现出与原版相似的诊断性能,可用于简化临床评估流程。
研究设计与样本
- 回顾性研究,纳入2016年1月至2025年7月期间接受MRI和根治性手术的连续直肠癌患者780例,中位年龄61岁(IQR 53-68岁),其中477例男性。
- 中心1患者进行淋巴结水平分析(251例直接手术患者,1302枚淋巴结;284例新辅助放化疗患者,918枚淋巴结),中心2和中心3患者进行患者水平外部验证。
- 两名放射科医生独立依据Node-RADS和ESGAR标准评估直肠系膜淋巴结。
关键影像表现/征象
- 在直接手术患者中,Node-RADS评分最佳阈值为≥3时诊断恶性淋巴结(Youden指数0.65),对应简化模型recSNAP。
- 在新辅助放化疗后患者中,Node-RADS评分阈值≥4时优于ESGAR标准(AUC 0.72 vs 0.66,P < .001)。
诊断标准与关键数值
- 直接手术患者中,recSNAP在淋巴结水平AUC为0.83,优于ESGAR标准的0.71(P < .001);患者水平AUC同样为0.83 vs 0.71(P < .001)。
- 新辅助放化疗患者中,Node-RADS阈值≥4时AUC为0.72,优于ESGAR标准的0.66(P < .001)。
- Node-RADS在治疗前和治疗后MRI的观察者间一致性Cohen κ分别为0.76和0.64。
临床应用与阅片要点
- Node-RADS可为直肠癌MRI淋巴结评估提供标准化分级系统,便于临床沟通和多学科讨论。
- 简化版recSNAP可降低评估复杂度,在不同治疗场景下(直接手术或新辅助后)选用不同阈值有助于优化诊断效能。
局限性
- 单中心回顾性研究设计,且中心1用于阈值确定和淋巴结水平分析,外部验证仅限患者水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Suboptimal nodal assessment in rectal cancer hampers pre- and postoperative assessment for treatment planning. A recently proposed standardized nodal evaluation system, Node Reporting and Data System 1.0 (Node-RADS), lacks robust evidence of diagnostic utility. Purpose To validate and optimize Node-RADS against European Society of Gastrointestinal and Abdominal Radiology (ESGAR) criteria in MRI-based nodal assessment in patients with rectal cancer, with subsequent patient-level external validation. Materials and Methods This retrospective study included consecutive patients with rectal cancer who underwent MRI and radical surgery between January 2016 and July 2025. Node-level analyses were performed in patients from center 1, and external patient-level validation was performed in patients from centers 2 and 3. Two radiologists independently evaluated mesorectal nodes according to Node-RADS and ESGAR criteria. The optimal threshold of the Node-RADS score for diagnosing malignancy was determined using the Youden index. Diagnostic performance and interobserver agreement were assessed using area under the receiver operating characteristic curve (AUC) and Cohen κ, respectively. Results This study included 780 patients (median age, 61 years [IQR, 53-68 years]; 477 men). Among 251 patients (1302 nodes) who underwent direct surgery, the optimal threshold of Node-RADS score was 3 or higher (Youden index, 0.65), enabling simplification to a modified model, the Simplified Nodal Assessment Process in Rectal Cancer (recSNAP). recSNAP outperformed the ESGAR criteria at both the node level (AUC, 0.83 vs 0.71; P < .001) and the patient level (AUC, 0.83 vs 0.71; P < .001). Similarly, among 284 patients (918 nodes) who received neoadjuvant chemoradiotherapy before surgery, Node-RADS with a threshold of 4 or higher outperformed the ESGAR criteria (AUC, 0.72 vs 0.66; P < .001). Interobserver agreement for Node-RADS at pre- and posttreatment MRI was substantial (Cohen κ, 0.76 and 0.64, respectively). Conclusion Node-RADS outperformed the ESGAR criteria for MRI-based rectal adenocarcinoma nodal assessment at both the node and patient levels and in external validation, and a simplified version of Node-RADS exhibited similar diagnostic performance. © RSNA, 2026 Supplemental material is available for this article.
引用
- Li, Guo, Wu, et al. Comparison of Diagnostic Performance of Node-RADS and ESGAR Criteria in Rectal Cancer Nodal Assessment at MRI. Radiology. 2026. PMID: 42578786. doi:10.1148/radiol.253676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。